怡達股份(300721.SZ):泰興怡達年產15萬噸環氧丙烷項目試生產(使用)方案通過專家論證
格隆匯12月21日丨怡達股份(300721.SZ)公佈,在當地政府的支持關心下,在建設單位的共同努力下,在各有關第三方的密切配合下,在主管部門和專家的嚴格要求和熱情指導下,經過公司項目人員的艱苦奮鬥、攻堅克難,公司控股子公司泰興怡達化學有限公司(“泰興怡達”)建設的“年產15萬噸環氧丙烷項目”已完成工程主體建設,設備安裝、調試及各項驗收工作,試生產(使用)方案經專家論證通過,符合試生產條件,進入試生產階段。泰興怡達將根據工藝的要求,先進行雙氧水裝置試生產,待雙氧水裝置試生產運行平穩併產出合格雙氧水產品後,再進行環氧丙烷裝置試生產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.